Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 10/20 | 0.54 |
| ▸ | JAK1 | P23458 | 11/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 10/20 | 0.53 |
| ▸ | JAK2 | O60674 | 7/20 | 0.53 |
| ▸ | FLT3 | P36888 | 4/20 | 0.52 |
| ▸ | TYK2 | P29597 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 5/20 | 0.49 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15056870 | 1.00 | AURKA (0.54) | AURKAJAK1AURKBJAK2FLT3 | |
| SCHEMBL15059487 | 0.92 | JAK1 (0.56) | AURKAJAK1AURKBJAK2FLT3 | |
| SCHEMBL15071798 | 0.92 | JAK1 (0.56) | AURKAJAK1AURKBJAK2FLT3 | |
| SCHEMBL15059489 | 0.92 | JAK1 (0.56) | AURKAJAK1AURKBJAK2FLT3 | |
| SCHEMBL15060153 | 0.92 | AURKA (0.48) | AURKAJAK1AURKBJAK2FLT3 | |
| SCHEMBL15059428 | 0.91 | AURKA (0.57) | AURKAJAK1AURKBJAK2FLT3 | |
| SCHEMBL15059747 | 0.89 | AURKB (0.50) | AURKAJAK1AURKBJAK2FLT3 | |
| SCHEMBL15058426 | 0.89 | AURKB (0.50) | AURKAJAK1AURKBJAK2FLT3 | |
| SCHEMBL15059878 | 0.89 | JAK1 (0.55) | AURKAJAK1AURKBJAK2FLT3 | |
| SCHEMBL15058314 | 0.89 | JAK1 (0.55) | AURKAJAK1AURKBJAK2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005281-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2015-01-01 | — | — | US | claimed |
| US-20150005281-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| US-20150005281-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| US-20150005281-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| WO-2013092854-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005281-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | JAK2, JAK1, JAK3 | AURKA 126/4885JAK1 2/4885AURKB 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.